The Cam-Path Forward

Authors


Corresponding author: Allan D. Kirk adkirk@emory.edu

Abstract

The author discusses the drug alemtuzumab as a case study in the benefits and drawbacks of off-label drug use in organ transplantation. See article by van den Hoogen et al on page 192.

Ancillary